Clinical trials: Hyperactivity
Attention Deficit Hyperactivity Disorder
Genetic Risk for Attention Deficit Hyperactivity Disorder Expressed in Brain Functioning
Poor inhibitory control has been proposed to be central to the cognitive deficits and symptomatology associated with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT00143832
- Where
- Netherlands
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
Attention Deficit Hyperactivity Disorder
Procedural Learning in Participants With ADHD
Skill acquisition refers to the process of improvement of performance following practice experience. This process is the basis for generation of a long-lasting memory.
- Trial name
- NCT00446537
- Testing
- Methylphenidate
- Where
- Israel
- Sponsor
- Shaare Zedek Medical Center
Attention Deficit Hyperactivity Disorder
Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents
To test the hypothesis that children/adolescents with ADHD, who are treated with atomoxetine hydrochloride in comparison to standard current therapies have greater improvements in their quality of life.
- Trial name
- NCT00191659
- Testing
- Atomoxetine Hydrochloride
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Tourette's Syndrome, Attention Deficit Hyperactivity Disorder
Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD
In the present study, we examine the question "Will day-time aggression in children improve when their night-time sleep is treated with pharmacological intervention (i.e.
- Trial name
- NCT00152750
- Testing
- APO-clonidine
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Attention Deficit Hyperactivity Disorder
Dietary Intake and Nutrient Status of Children With ADHD
Assess the dietary intake of children aged 6-12 years by means of a 24-hour recall and 3-day food record and asses the nutrient status of Vitamin B6, serum ferritin, serum zinc and serum copper of the same children by means of…
- Trial name
- NCT00434928
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Attention-Deficit/Hyperactivity Disorder, Comorbid Dyslexia
Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
The purpose of this study is to assess the efficacy and safety of atomoxetine administered once daily in the treatment of children and adolescents with ADHD and comorbid dyslexia.
- Trial name
- NCT00191048
- Testing
- Atomoxetine
- Where
- 8 sites in United States
- Volunteers
- 105 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder
A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by patients, parents and physicians, and its impact on…
- Trial name
- NCT00191516
- Testing
- Atomoxetine
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Eli Lilly and Company
Attention-Deficit/Hyperactivity Disorder
Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes
The purpose of this study is to assess whether changes in the symptoms of ADHD show a relationship with changes in functioning in children with ADHD treated with atomoxetine over a 3-month period.
- Trial name
- NCT00191633
- Testing
- Atomoxetine
- Where
- 19 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder
A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by patients, parents and physicians, and its impact on…
- Trial name
- NCT00191737
- Testing
- Atomoxetine
- Where
- 2 sites in Germany
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Neuropsychological Functioning in Children With Attention-Deficit/Hyperactivity Disorder.
The purpose of this study is to evaluate the change in neuropsychological status from baseline to 6 months post-initiation of atomoxetine treatment in children ages 6 to 10.5 diagnosed with ADHD.
- Trial name
- NCT00216918
- Testing
- Atomoxetine Hydrochloride
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Attention-Deficit/Hyperactivity Disorder
Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD
The purpose of this study is to assess the efficacy, safety and tolerability of atomoxetine administered once daily in the treatment of adolescents with ADHD after 8 weeks and after 52 weeks
- Trial name
- NCT00191035
- Testing
- Atomoxetine
- Where
- 21 sites in United States
- Volunteers
- 520 people
- Sponsor
- Eli Lilly and Company
Attention-Deficit/Hyperactivity Disorder
Supplementation of Phosphatidylserine (PS) and n-3 Long Chain Fatty Acids (EPA, DHA) in Children With ADHD
To determine whether supplementation of omega-3 long-chain polyunsaturated fatty acid conjugated to phosphatidylserine rather than triglycerides (fish oil) could affect Attention-deficit/hyperactivity disorder symptoms in…
- Trial name
- NCT00382616
- Testing
- Phosphatidylserine-Omega3
- Where
- Israel
- Volunteers
- 90 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Attention Disorder With Hyperactivity (ADHD)
Sleep Disorders in Children With ADHD
ADHD is often associated with sleep difficulties. Attention-deficit/hyperactivity disorder (ADHD) is the most common problem presented to children mental health services.
- Trial name
- NCT00224731
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Hvolby, Allan, M.D.
Attention Deficit Hyperactivity Disorder
Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents
Comparison of the effect of Atomoxetine and psychoeducation with placebo and psychoeducation after 10 weeks of treatment
- Trial name
- NCT00191542
- Testing
- Atomoxetine
- Where
- 9 sites in Sweden
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder
Open-label trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 years with Attention- Deficit/Hyperactivity Disorder
- Trial name
- NCT00191880
- Testing
- atomoxetine
- Where
- 8 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder
The overall primary objective of this study is to test the hypothesis that, compared with placebo,administration of atomoxetine will result in an improved work productivity.
- Trial name
- NCT00190931
- Testing
- Atomoxetine Hydrochloride
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
Attention-Deficit/Hyperactivity Disorder (ADHD), Insomnia
Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents
Children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) very commonly experience difficulty in initiating and maintaining sleep.
- Trial name
- NCT00252278
- Testing
- atomoxetine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Rhode Island Hospital
Aggression
Risperidone Augmentation for Treatment-Resistant Aggression in ADHD
Primary objectives: 1. To assess the short-term efficacy of risperidone augmentation for treatment-resistant aggression in children with ADHD. 2.
- Trial name
- NCT00297739
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Armenteros, Jorge L., M.D., P.A.
ADHD
Methylphenidate and Driving Ability in Adult Patients With Attention-Deficit Hyperactivity Disorder
The primary purpose of this study is to determine the effects of methylphenidate versus placebo on driving ability of adult ADHD patients.
- Trial name
- NCT00223561
- Testing
- methylphenidate
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- Utrecht Institute for Pharmaceutical Sciences
Attention Deficit Hyperactivity Disorder
Genetic Liability in the Brain Morphology of Attention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder (ADHD) is a heritable psychiatric disorder with onset in childhood. Twin and adoption studies indicate that additive genetic factors explain up to 80% of the variance underlying…
- Trial name
- NCT00161161
- Where
- Netherlands
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht